Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin
Travel Med Infect Dis
.
2021 Jan-Feb:39:101954.
doi: 10.1016/j.tmaid.2020.101954.
Epub 2020 Dec 13.
Authors
Matthieu Million
1
,
Audrey Giraud-Gatineau
2
,
Jean-Christophe Lagier
3
,
Philippe Parola
4
,
Philippe Gautret
3
,
Didier Raoult
3
Affiliations
1
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France. Electronic address:
[email protected]
.
2
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ., IRD, AP-HM, SSA, VITROME, Marseille, France; Assistance Publique- Hôpitaux de Marseille (AP-HM), Marseille, France; Centre D'Epidémiologie et de Santé Publique des Armées (CESPA), Marseille, France.
3
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France.
4
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ., IRD, AP-HM, SSA, VITROME, Marseille, France.
PMID:
33316396
PMCID:
PMC7733546
DOI:
10.1016/j.tmaid.2020.101954
No abstract available
Publication types
Comment
MeSH terms
Azithromycin / therapeutic use
COVID-19 Drug Treatment*
Drug Therapy, Combination
France
Humans
Hydroxychloroquine* / therapeutic use
Retrospective Studies
SARS-CoV-2
Substances
Hydroxychloroquine
Azithromycin